This application is a competitive renewal of the Dana-Farber/Harvard Cancer Center (DF/HCC) Lung Cancer Specialized Program in Research Excellence (SPORE). The Dana-Farber/Harvard Cancer Center Lung Cancer SPORE includes investigators from the Harvard-affiliated hospitals in Boston, Harvard Medical School, and the Harvard School of Public Health. This DF/HCC Lung Cancer SPORE will build on the strengths of established ongoing scientific investigation within the DF/HCC. Five major projects are proposed. Project 1 will use single nucleotide polymorphisms in germline DMA to examine their associations with patient outcome following treatment for non-small cell lung cancer. Project 2 will examine the transcription factors Foxa2 and the C/EBP family members in the pathogenesis and potential treatment of lung cancer. Project 3 plans to target erlotinib-resistant lung cancer with other tyrosine kinase inhibitors and irradiation to provide further information on effective combinations of targeted agents. Project 4 will characterize the effect of Hsp90 inhibitors in NSCLCs with different genomic changes to help identify patients who may benefit from this therapy. Project 5 will study the mechanisms of acquired resistance to epidermal growth factor receptor-targeted agents in cell lines and human trials for patients with lung cancer. The 4 cores established in 2003 integrate these Projects. These include 1) Tissue and Pathology Core, 2) Administration, Evaluation and Planning Core, 3) Biostatistics Core, 4) Genomics and Bioinformatics Core. This SPORE application describes a Development Research Program that includes our past performance and plan for selection of new projects. The Career Development Program describes our recipients and outlines the mechanism for the identification and support of talented young investigators in lung cancer. The Developmental Research and Career Development Programs will provide the focus for involvement of the community in planning and financial support of the DF/HCC Lung Cancer SPORE. The goal of the DF/HCC Lung Cancer SPORE is to continue the translation of biological and technological advances into clinically meaningful advances for patients with lung cancer and at risk for lung cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Program Officer
Ujhazy, Peter
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Vanderlaan, Paul A; Yamaguchi, Norihiro; Folch, Erik et al. (2014) Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer 84:39-44
Lau, Allison N; Curtis, Stephen J; Fillmore, Christine M et al. (2014) Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J 33:468-81
Zhai, Rihong; Yu, Xiaojin; Wei, Yongyue et al. (2014) Smoking and smoking cessation in relation to the development of co-existing non-small cell lung cancer with chronic obstructive pulmonary disease. Int J Cancer 134:961-70
Oxnard, Geoffrey R; Paweletz, Cloud P; Kuang, Yanan et al. (2014) Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 20:1698-705
Nishino, M; Jackman, D M; DiPiro, P J et al. (2014) Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy. Clin Radiol 69:841-8
Hata, Aaron N; Yeo, Alan; Faber, Anthony C et al. (2014) Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Res 74:3146-56
Wang, Yufei; McKay, James D; Rafnar, Thorunn et al. (2014) Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet 46:736-41
Zhai, Rihong; Yu, Xiaojin; Shafer, Andrea et al. (2014) The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection. Chest 145:346-53
de Figueiredo-Pontes, Lorena Lobo; Wong, Daisy Wing-Sze; Tin, Vicky Pui-Chi et al. (2014) Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer. J Thorac Oncol 9:248-53
Li, Guangyuan; Wang, Xiaoqi; Hibshoosh, Hanina et al. (2014) Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1. PLoS One 9:e106349

Showing the most recent 10 out of 137 publications